{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:39:58Z","timestamp":1790836798677,"version":"4.1.0"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Jilin Provincial Science and Technology Department","award":["20111807"],"award-info":[{"award-number":["20111807"]}]},{"name":"Jilin Provincial Science and Technology Department","award":["20140414014GH"],"award-info":[{"award-number":["20140414014GH"]}]},{"name":"Jilin Provincial Science and Technology Department","award":["20150101176"],"award-info":[{"award-number":["20150101176"]}]},{"name":"Platform Construction Project of Development and Reform Commission of Jilin Province","award":["2014N147"],"award-info":[{"award-number":["2014N147"]}]},{"name":"the Bethune Program B of Jilin University","award":["2012202"],"award-info":[{"award-number":["2012202"]}]},{"name":"National Major Scientific and Technological Special Project","award":["2013ZX09102032"],"award-info":[{"award-number":["2013ZX09102032"]}]},{"name":"the Key Scientific Project of Jilin Province","award":["20140204024YY"],"award-info":[{"award-number":["20140204024YY"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12967-017-1152-5","type":"journal-article","created":{"date-parts":[[2017,2,27]],"date-time":"2017-02-27T08:24:23Z","timestamp":1488183863000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Heterogeneity of Toll-like receptor 9 signaling in B cell malignancies and its potential therapeutic application"],"prefix":"10.1186","volume":"15","author":[{"given":"Ling","family":"Bai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingtao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiuwei","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,2,27]]},"reference":[{"key":"1152_CR1","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s40265-014-0338-x","volume":"75","author":"JE Arnason","year":"2015","unstructured":"Arnason JE, Brown JR. Targeted therapy for chronic lymphocytic leukemia: current status and future directions. Drugs. 2015;75:143\u201355.","journal-title":"Drugs"},{"key":"1152_CR2","first-page":"217593","volume":"2015","author":"JF Rossi","year":"2015","unstructured":"Rossi JF. Targeted therapies in adult B-cell malignancies. Biomed Res Int. 2015;2015:217593.","journal-title":"Biomed Res Int"},{"key":"1152_CR3","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/nri1150","volume":"3","author":"OJ Finn","year":"2003","unstructured":"Finn OJ. Cancer vaccines: between the idea and the reality. Nat Rev Immunol. 2003;3:630\u201341.","journal-title":"Nat Rev Immunol"},{"key":"1152_CR4","first-page":"143","volume":"4","author":"F Naddafi","year":"2015","unstructured":"Naddafi F, Davami F. Anti-CD19 monoclonal antibodies: a new approach to lymphoma therapy. Int J Mol Cell Med. 2015;4:143.","journal-title":"Int J Mol Cell Med"},{"key":"1152_CR5","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/321209a0","volume":"321","author":"AP Bird","year":"1986","unstructured":"Bird AP. CpG-rich islands and the function of DNA methylation. Nature. 1986;321:209\u201313.","journal-title":"Nature"},{"key":"1152_CR6","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1365-2567.2007.02761.x","volume":"124","author":"C Berges","year":"2008","unstructured":"Berges C, Haberstock H, Fuchs D, Miltz M, Sadeghi M, Opelz G, et al. Proteasome inhibition suppresses essential immune functions of human CD4+ T cells. Immunology. 2008;124:234\u201346.","journal-title":"Immunology"},{"key":"1152_CR7","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nchembio.481","volume":"7","author":"JA Paolo Di","year":"2011","unstructured":"Di Paolo JA, Huang T, Balazs M, Barbosa J, Barck KH, Bravo BJ, et al. Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis. Nat Chem Biol. 2011;7:41\u201350.","journal-title":"Nat Chem Biol"},{"key":"1152_CR8","doi-asserted-by":"crossref","first-page":"448","DOI":"10.3389\/fimmu.2015.00448","volume":"6","author":"R Zappasodi","year":"2015","unstructured":"Zappasodi R, de Braud F, Di Nicola M. Lymphoma immunotherapy: current status. Front Immunol. 2015;6:448.","journal-title":"Front Immunol"},{"key":"1152_CR9","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/sji.12331","volume":"82","author":"CL Lorentzen","year":"2015","unstructured":"Lorentzen CL, Straten PT. CD19-chimeric antigen receptor t cells for treatment of chronic lymphocytic leukaemia and acute lymphoblastic leukaemia. Scand J Immunol. 2015;82:307\u201319.","journal-title":"Scand J Immunol"},{"key":"1152_CR10","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1182\/blood-2008-02-140673","volume":"112","author":"D Chiron","year":"2008","unstructured":"Chiron D, Bekeredjian-Ding I, Pellat-Deceunynck C, Bataille R, Jego G. Toll-like receptors: lessons to learn from normal and malignant human B cells. Blood. 2008;112:2205\u201313.","journal-title":"Blood"},{"key":"1152_CR11","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1189\/jlb.69.1.81","volume":"69","author":"B Jahrsd\u00f6rfer","year":"2001","unstructured":"Jahrsd\u00f6rfer B, Hartmann G, Racila E, Jackson W, M\u00fchlenhoff L, Meinhardt G, et al. CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens. J Leukoc Biol. 2001;69:81\u20138.","journal-title":"J Leukoc Biol"},{"key":"1152_CR12","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s10875-010-9456-8","volume":"31","author":"S Agrawal","year":"2011","unstructured":"Agrawal S, Gupta S. TLR1\/2, TLR7, and TLR9 signals directly activate human peripheral blood naive and memory B cell subsets to produce cytokines, chemokines, and hematopoietic growth factors. J Clin Immunol. 2011;31:89\u201398.","journal-title":"J Clin Immunol"},{"key":"1152_CR13","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/path.2264","volume":"214","author":"I Sabroe","year":"2008","unstructured":"Sabroe I, Parker LC, Dower SK, Whyte MKB. The role of TLR activation in inflammation. J Pathol. 2008;214:126\u201335.","journal-title":"J Pathol"},{"key":"1152_CR14","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.intimp.2010.09.012","volume":"11","author":"K Maruyama","year":"2011","unstructured":"Maruyama K, Selmani Z, Ishii KH, Yamaguchi K. Innate immunity and cancer therapy. Int Immunopharmacol. 2011;11:350\u20137.","journal-title":"Int Immunopharmacol"},{"key":"1152_CR15","doi-asserted-by":"crossref","first-page":"5041","DOI":"10.1182\/blood-2009-03-213363","volume":"115","author":"X Liang","year":"2010","unstructured":"Liang X, Moseman EA, Farrar MA, Bachanova V, Weisdorf DJ, Blazar BR, et al. Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells. Blood. 2010;115:5041\u201352.","journal-title":"Blood"},{"key":"1152_CR16","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s12253-009-9162-0","volume":"15","author":"T Ren","year":"2009","unstructured":"Ren T, Xu L, Jiao S, Wang Y, Cai Y, Liang Y, et al. TLR9 signaling promotes tumor progression of human lung cancer cell in vivo. Pathol Oncol Res. 2009;15:623\u201330.","journal-title":"Pathol Oncol Res"},{"key":"1152_CR17","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.4049\/jimmunol.179.4.2493","volume":"179","author":"J Li","year":"2007","unstructured":"Li J, Song W, Czerwinski DK, Varghese B, Uematsu S, Akira S, et al. Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself. J Immunol. 2007;179:2493\u2013500.","journal-title":"J Immunol"},{"key":"1152_CR18","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1200\/JCO.2010.28.9793","volume":"28","author":"JD Brody","year":"2010","unstructured":"Brody JD, Ai WZ, Czerwinski DK, Torchia JA, Levy M, Advani RH, et al. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I\/II study. J Clin Oncol. 2010;28:4324\u201332.","journal-title":"J Clin Oncol"},{"key":"1152_CR19","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.1140488","volume":"317","author":"S Rakoff-Nahoum","year":"2007","unstructured":"Rakoff-Nahoum S, Medzhitov R. Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science. 2007;317:124\u20137.","journal-title":"Science"},{"key":"1152_CR20","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1073\/pnas.0708594105","volume":"105","author":"JB Swann","year":"2008","unstructured":"Swann JB, Vesely MD, Silva A, Sharkey J, Akira S, Schreiber RD, et al. Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proc Natl Acad Sci USA. 2008;105:652\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1152_CR21","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/j.1365-2141.2005.05893.x","volume":"132","author":"SL Corthals","year":"2006","unstructured":"Corthals SL, Wynne K, She K, Shimizu H, Curman D, Garbutt K, et al. Differential immune effects mediated by Toll-like receptors stimulation in precursor B-cell acute lymphoblastic leukaemia. Br J Haematol. 2006;132:452\u20138.","journal-title":"Br J Haematol"},{"key":"1152_CR22","doi-asserted-by":"crossref","first-page":"e323","DOI":"10.1038\/cddis.2012.60","volume":"3","author":"J Noack","year":"2012","unstructured":"Noack J, Jordi M, Zauner L, Alessi D, Burch A, Tinguely M, et al. TLR9 agonists induced cell death in Burkitt\u2019s lymphoma cells is variable and influenced by TLR9 polymorphism. Cell Death Dis. 2012;3:e323.","journal-title":"Cell Death Dis"},{"key":"1152_CR23","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1038\/sj.leu.2404225","volume":"20","author":"J Bohnhorst","year":"2006","unstructured":"Bohnhorst J, Rasmussen T, Moen SH, Fl\u00f8ttum M, Knudsen L, B\u00f8rset M, et al. Toll-like receptors mediate proliferation and survival of multiple myeloma cells. Leukemia. 2006;20:1138\u201344.","journal-title":"Leukemia"},{"key":"1152_CR24","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jim.2005.02.012","volume":"300","author":"M Henault","year":"2005","unstructured":"Henault M, Lee LN, Evans GF, Zuckerman SH. The human Burkitt lymphoma cell line Namalwa represents a homogenous cell system characterized by high levels of Toll-like receptor 9 and activation by CpG oligonucleotides. J Immunol Methods. 2005;300:93\u20139.","journal-title":"J Immunol Methods"},{"key":"1152_CR25","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/j.1749-6632.2009.04615.x","volume":"1173","author":"V Buh\u00e9","year":"2009","unstructured":"Buh\u00e9 V, Guerrier T, Youinou P, Berthou C, Loisel S. CpG ODN enhances the efficacy of rituximab in non-Hodgkin lymphoma. Ann NY Acad Sci. 2009;1173:858\u201364.","journal-title":"Ann NY Acad Sci"},{"key":"1152_CR26","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/90609","volume":"2","author":"S Akira","year":"2001","unstructured":"Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol. 2001;2:675\u201380.","journal-title":"Nat Immunol"},{"key":"1152_CR27","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1084\/jem.20070763","volume":"205","author":"C Guiducci","year":"2008","unstructured":"Guiducci C, Ghirelli C, Marloie-Provost MA, Matray T, Coffman RL, Liu YJ, et al. PI3K is critical for the nuclear translocation of IRF-7 and type I IFN production by human plasmacytoid predendritic cells in response to TLR activation. J Exp Med. 2008;205:315\u201322.","journal-title":"J Exp Med"},{"key":"1152_CR28","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.addr.2007.12.004","volume":"60","author":"Y Kumagai","year":"2008","unstructured":"Kumagai Y, Takeuchi O, Akira S. TLR9 as a key receptor for the recognition of DNA. Adv Drug Deliv Rev. 2008;60:795\u2013804.","journal-title":"Adv Drug Deliv Rev"},{"key":"1152_CR29","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.immuni.2006.08.009","volume":"25","author":"K Honda","year":"2006","unstructured":"Honda K, Takaoka A, Taniguchi T. Type I interferon [corrected] gene induction by the interferon regulatory factor family of transcription factors. Immunity. 2006;25:349\u201360.","journal-title":"Immunity"},{"key":"1152_CR30","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1002\/eji.200636984","volume":"37","author":"W Jiang","year":"2007","unstructured":"Jiang W, Lederman MM, Harding CV, Rodriguez B, Mohner RJ, Sieg SF. TLR9 stimulation drives naive B cells to proliferate and to attain enhanced antigen presenting function. Eur J Immunol. 2007;37:2205\u201313.","journal-title":"Eur J Immunol"},{"key":"1152_CR31","doi-asserted-by":"crossref","first-page":"3969","DOI":"10.1182\/blood-2008-10-185421","volume":"113","author":"J Eckl-Dorna","year":"2009","unstructured":"Eckl-Dorna J, Batista FD. BCR-mediated uptake of antigen linked to TLR9 ligand stimulates B-cell proliferation and antigen-specific plasma cell formation. Blood. 2009;113:3969\u201377.","journal-title":"Blood"},{"key":"1152_CR32","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.2217\/imt.12.117","volume":"4","author":"F Glehn Von","year":"2012","unstructured":"Von Glehn F, Santos LM, Balashov KE. Plasmacytoid dendritic cells and immunotherapy in multiple sclerosis. Immunotherapy. 2012;4:1053\u201361.","journal-title":"Immunotherapy"},{"key":"1152_CR33","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1517\/14728222.2010.501333","volume":"14","author":"X Huang","year":"2010","unstructured":"Huang X, Yang Y. Targeting the TLR9-MyD88 pathway in the regulation of adaptive immune responses. Expert Opin Ther Targets. 2010;14:787\u201396.","journal-title":"Expert Opin Ther Targets"},{"key":"1152_CR34","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.coi.2005.03.003","volume":"17","author":"SL Peng","year":"2005","unstructured":"Peng SL. Signaling in B cells via Toll-like receptors. Curr Opin Immunol. 2005;17:230\u20136.","journal-title":"Curr Opin Immunol"},{"key":"1152_CR35","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1600-065X.2007.00572.x","volume":"220","author":"AM Krieg","year":"2007","unstructured":"Krieg AM, Vollmer J. Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity. Immunol Rev. 2007;220:251\u201369.","journal-title":"Immunol Rev"},{"key":"1152_CR36","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/intimm\/dxv045","volume":"27","author":"M Gray","year":"2015","unstructured":"Gray M, Gray D. Regulatory B cells mediate tolerance to apoptotic self in health: implications for disease. Int Immunol. 2015;27:505\u201311.","journal-title":"Int Immunol"},{"key":"1152_CR37","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jaut.2014.02.005","volume":"51","author":"T Guerrier","year":"2014","unstructured":"Guerrier T, Pochard P, Lahiri A, Youinou P, Pers JO, Jamin C. TLR9 expressed on plasma membrane acts as a negative regulator of human B cell response. J Autoimmun. 2014;51:23\u20139.","journal-title":"J Autoimmun"},{"key":"1152_CR38","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1126\/science.1078231","volume":"299","author":"C Pasare","year":"2003","unstructured":"Pasare C, Medzhitov R. Toll pathway-dependent blockade of CD4+ CD25+ T cell-mediated suppression by dendritic cells. Science. 2003;299:1033\u20136.","journal-title":"Science"},{"key":"1152_CR39","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/ni1059","volume":"5","author":"Y Yang","year":"2004","unstructured":"Yang Y, Huang CT, Huang X, Pardoll DM. Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat Immunol. 2004;5:508\u201315.","journal-title":"Nat Immunol"},{"key":"1152_CR40","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/sj.onc.1210910","volume":"27","author":"H Conroy","year":"2008","unstructured":"Conroy H, Marshall NA, Mills KHG. TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours. Oncogene. 2008;27:168\u201380.","journal-title":"Oncogene"},{"key":"1152_CR41","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/eji.200737184","volume":"37","author":"P Puccetti","year":"2007","unstructured":"Puccetti P. On watching the watchers: IDO and type I\/II IFN. Eur J Immunol. 2007;37:876\u20139.","journal-title":"Eur J Immunol"},{"key":"1152_CR42","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.it.2005.11.005","volume":"27","author":"D Duin Van","year":"2006","unstructured":"Van Duin D, Medzhitov R, Shaw AC. Triggering TLR signaling in vaccination. Trends Immunol. 2006;27:49\u201355.","journal-title":"Trends Immunol"},{"key":"1152_CR43","doi-asserted-by":"crossref","first-page":"954","DOI":"10.4049\/jimmunol.172.2.954","volume":"172","author":"M Wagner","year":"2004","unstructured":"Wagner M, Poeck H, Jahrsdoerfer B, Rothenfusser S, Prell D, Bohle B, et al. IL-12p70-dependent Th1 induction by human B cells requires combined activation with CD40 ligand and CpG DNA. J Immunol. 2004;172:954\u201363.","journal-title":"J Immunol"},{"key":"1152_CR44","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.jaci.2015.08.040","volume":"137","author":"H Morbach","year":"2016","unstructured":"Morbach H, Schickel JN, Cunningham-Rundles C, Conley ME, Reisli I, Franco JL, et al. CD19 controls Toll-like receptor 9 responses in human B cells. J Allergy Clin Immunol. 2016;137:889\u201398.","journal-title":"J Allergy Clin Immunol"},{"key":"1152_CR45","doi-asserted-by":"crossref","first-page":"e74103","DOI":"10.1371\/journal.pone.0074103","volume":"8","author":"EF Kenny","year":"2013","unstructured":"Kenny EF, Quinn SR, Doyle SL, Vink PM, van Eenennaam H, O\u2019Neill LA. Bruton\u2019s tyrosine kinase mediates the synergistic signalling between TLR9 and the B cell receptor by regulating calcium and calmodulin. PLoS ONE. 2013;8:e74103.","journal-title":"PLoS ONE"},{"key":"1152_CR46","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1749-6632.2009.05152.x","volume":"1183","author":"R Lande","year":"2010","unstructured":"Lande R, Gilliet M. Plasmacytoid dendritic cells: key players in the initiation and regulation of immune responses. Ann NY Acad Sci. 2010;1183:89\u2013103.","journal-title":"Ann NY Acad Sci"},{"key":"1152_CR47","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1051\/medsci\/200521173","volume":"21","author":"AF Carpentier","year":"2005","unstructured":"Carpentier AF. Cancer immunotherapy with CpG-ODN. Med Sci (Paris). 2005;21:73\u20137.","journal-title":"Med Sci (Paris)."},{"key":"1152_CR48","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.4049\/jimmunol.166.4.2372","volume":"166","author":"D Verthelyi","year":"2001","unstructured":"Verthelyi D, Ishii KJ, Gursel M, Takeshita F, Klinman DM. Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs. J Immunol. 2001;166:2372\u20137.","journal-title":"J Immunol"},{"key":"1152_CR49","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S0198-8859(02)00749-8","volume":"63","author":"S Rothenfusser","year":"2002","unstructured":"Rothenfusser S, Tuma E, Endres S, Hartmann G. Plasmacytoid dendritic cells: the key to CpG. Hum Immunol. 2002;63:1111\u20139.","journal-title":"Hum Immunol"},{"key":"1152_CR50","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/eji.200324032","volume":"34","author":"J Vollmer","year":"2004","unstructured":"Vollmer J, Weeratna R, Payette P, Jurk M, Schetter C, Laucht M, et al. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol. 2004;34:251\u201362.","journal-title":"Eur J Immunol"},{"key":"1152_CR51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2004.02.022","volume":"97","author":"GK Mutwiri","year":"2004","unstructured":"Mutwiri GK, Nichani AK, Babiuk S, Babiuk LA. Strategies for enhancing the immunostimulatory effects of CpG oligodeoxynucleotides. J Control Release. 2004;97:1\u201317.","journal-title":"J Control Release"},{"key":"1152_CR52","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/S0026-895X(25)10208-3","volume":"45","author":"H Sands","year":"1994","unstructured":"Sands H, Gorey-Feret LJ, Cocuzza AJ, Hobbs FW, Chidester D, Trainor GL. Biodistribution and metabolism of internally 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate. Mol Pharmacol. 1994;45:932\u201343.","journal-title":"Mol Pharmacol"},{"key":"1152_CR53","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1182\/blood-2013-07-517987","volume":"123","author":"DMS Hossain","year":"2014","unstructured":"Hossain DMS, Dos Santos C, Zhang Q, Kozlowska A, Liu H, Gao C, et al. Leukemia cell\u2013targeted STAT3 silencing and TLR9 triggering generate systemic antitumor immunity. Blood. 2014;123:15\u201325.","journal-title":"Blood"},{"key":"1152_CR54","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1182\/blood-2012-07-442590","volume":"121","author":"Q Zhang","year":"2013","unstructured":"Zhang Q, Hossain DMS, Nechaev S, Kozlowska A, Zhang W, Liu Y, et al. TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo. Blood. 2013;121:1304\u201315.","journal-title":"Blood"},{"key":"1152_CR55","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.immuni.2007.09.002","volume":"27","author":"T Dorner","year":"2007","unstructured":"Dorner T, Radbruch A. Antibodies and B cell memory in viral immunity. Immunity. 2007;27:384\u201392.","journal-title":"Immunity"},{"key":"1152_CR56","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1365-2567.2006.02392.x","volume":"118","author":"A M\u00e5nsson","year":"2006","unstructured":"M\u00e5nsson A, Adner M, H\u00f6ckerfelt U, Cardell LO. A distinct Toll-like receptor repertoire in human tonsillar B cells, directly activated by PamCSK, R-837 and CpG-2006 stimulation. Immunology. 2006;118:539\u201348.","journal-title":"Immunology"},{"key":"1152_CR57","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1182\/blood-2002-11-3569","volume":"101","author":"NL Bernasconi","year":"2003","unstructured":"Bernasconi NL, Onai N, Lanzavecchia A. A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. Blood. 2003;101:4500\u20134.","journal-title":"Blood"},{"key":"1152_CR58","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1177\/1753425916651985","volume":"22","author":"MA Pettengill","year":"2016","unstructured":"Pettengill MA, van Haren SD, Li N, Dowling DJ, Bergelson I, Jans J, et al. Distinct TLR-mediated cytokine production and immunoglobulin secretion in human newborn naive B cells. Innate Immun. 2016;22:433\u201343.","journal-title":"Innate Immun"},{"key":"1152_CR59","doi-asserted-by":"crossref","first-page":"5898","DOI":"10.4049\/jimmunol.160.12.5898","volume":"160","author":"AK Yi","year":"1998","unstructured":"Yi AK, Chang M, Peckham DW, Krieg AM, Ashman RF. CpG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry. J Immunol. 1998;160:5898\u2013906.","journal-title":"J Immunol."},{"key":"1152_CR60","doi-asserted-by":"crossref","first-page":"e87299","DOI":"10.1371\/journal.pone.0087299","volume":"9","author":"PA Nikitin","year":"2014","unstructured":"Nikitin PA, Price AM, McFadden K, Yan CM, Luftig MA. Mitogen-induced B-cell proliferation activates Chk2-dependent G1\/S cell cycle arrest. PLoS ONE. 2014;9:e87299.","journal-title":"PLoS ONE"},{"key":"1152_CR61","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1002\/eji.200636878","volume":"37","author":"H Azulay-Debby","year":"2007","unstructured":"Azulay-Debby H, Edry E, Melamed D. CpG DNA stimulates autoreactive immature B cells in the bone marrow. Eur J Immunol. 2007;37:1463\u201375.","journal-title":"Eur J Immunol"},{"key":"1152_CR62","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1158\/1078-0432.CCR-04-1890","volume":"11","author":"B Jahrsdorfer","year":"2005","unstructured":"Jahrsdorfer B, M\u00fchlenhoff L, Blackwell SE, Wagner M, Poeck H, Hartmann E, et al. B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides. Clin Cancer Res. 2005;11:1490\u20139.","journal-title":"Clin Cancer Res"},{"key":"1152_CR63","doi-asserted-by":"crossref","first-page":"675","DOI":"10.3892\/ijo.2016.3569","volume":"49","author":"M Sanchez-Cuaxospa","year":"2016","unstructured":"Sanchez-Cuaxospa M, Contreras-Ramos A, Perez-Figueroa E, Medina-Sanson A, Jimenez-Hernandez E, Torres-Nava JR, et al. Low expression of Toll-like receptors in peripheral blood mononuclear cells of pediatric patients with acute lymphoblastic leukemia. Int J Oncol. 2016;49:675\u201381.","journal-title":"Int J Oncol"},{"key":"1152_CR64","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jaut.2012.05.012","volume":"39","author":"T Guerrier","year":"2012","unstructured":"Guerrier T, Youinou P, Pers JO, Jamin C. TLR9 drives the development of transitional B cells towards the marginal zone pathway and promotes autoimmunity. J Autoimmun. 2012;39:173\u20139.","journal-title":"J Autoimmun"},{"key":"1152_CR65","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/sj.leu.2404417","volume":"21","author":"PG Longo","year":"2007","unstructured":"Longo PG, Laurenti L, Gobessi S, Petlickovski A, Pelosi M, Chiusolo P, et al. The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease. Leukemia. 2007;21:110\u201320.","journal-title":"Leukemia"},{"key":"1152_CR66","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3109\/10428194.2011.608451","volume":"53","author":"CS Zent","year":"2012","unstructured":"Zent CS, Smith BJ, Ballas ZK, Wooldridge JE, Link BK, Call TG, et al. Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia. Leuk Lymphoma. 2012;53:211\u20137.","journal-title":"Leuk Lymphoma"},{"key":"1152_CR67","doi-asserted-by":"crossref","first-page":"944","DOI":"10.4049\/jimmunol.164.2.944","volume":"164","author":"G Hartmann","year":"2000","unstructured":"Hartmann G, Krieg AM. Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J Immunol. 2000;164:944\u201353.","journal-title":"J Immunol"},{"key":"1152_CR68","doi-asserted-by":"crossref","first-page":"4909","DOI":"10.1158\/0008-5472.CAN-04-4124","volume":"65","author":"L Farhana","year":"2005","unstructured":"Farhana L, Dawson MI, Fontana JA. Apoptosis induction by a novel retinoid-related molecule requires nuclear factor-kappaB activation. Cancer Res. 2005;65:4909\u201317.","journal-title":"Cancer Res"},{"key":"1152_CR69","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.4049\/jimmunol.159.5.2212","volume":"159","author":"A Ogata","year":"1997","unstructured":"Ogata A, Chauhan D, Teoh G, Treon SP, Urashima M, Schlossman RL, et al. IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. J Immunol. 1997;159:2212\u201321.","journal-title":"J Immunol"},{"key":"1152_CR70","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.3324\/haematol.2011.044792","volume":"96","author":"E Arvaniti","year":"2011","unstructured":"Arvaniti E, Ntoufa S, Papakonstantinou N, Touloumenidou T, Laoutaris N, Anagnostopoulos A, et al. Toll-like receptor signaling pathway in chronic lymphocytic leukemia: distinct gene expression profiles of potential pathogenic significance in specific subsets of patients. Haematologica. 2011;96:1644\u201352.","journal-title":"Haematologica"},{"key":"1152_CR71","doi-asserted-by":"crossref","first-page":"4518","DOI":"10.4049\/jimmunol.1302102","volume":"192","author":"M Chatzouli","year":"2014","unstructured":"Chatzouli M, Ntoufa S, Papakonstantinou N, Chartomatsidou E, Anagnostopoulos A, Kollia P, et al. Heterogeneous functional effects of concomitant B cell receptor and TLR stimulation in chronic lymphocytic leukemia with mutated versus unmutated Ig genes. J Immunol. 2014;192:4518\u201324.","journal-title":"J Immunol"},{"key":"1152_CR72","doi-asserted-by":"crossref","first-page":"901","DOI":"10.4049\/jimmunol.1403189","volume":"195","author":"PK Mongini","year":"2015","unstructured":"Mongini PK, Gupta R, Boyle E, Nieto J, Lee H, Stein J, et al. TLR-9 and IL-15 synergy promotes the in vitro clonal expansion of chronic lymphocytic leukemia B cells. J Immunol. 2015;195:901\u201323.","journal-title":"J Immunol"},{"key":"1152_CR73","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/ijc.30444","volume":"104","author":"M Feist","year":"2017","unstructured":"Feist M, Kemper J, Taruttis F, Rehberg T, Engelmann JC, Gronwald W, et al. Synergy of interleukin 10 and Toll-like receptor 9 signalling in B cell proliferation: implications for lymphoma pathogenesis. Int J Cancer. 2017;104:1147\u201358.","journal-title":"Int J Cancer"},{"key":"1152_CR74","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/cmi.2013.14","volume":"10","author":"N Arunkumar","year":"2013","unstructured":"Arunkumar N, Liu C, Hang H, Song W. Toll-like receptor agonists induce apoptosis in mouse B-cell lymphoma cells by altering NF-kappaB activation. Cell Mol Immunol. 2013;10:360\u201372.","journal-title":"Cell Mol Immunol"},{"key":"1152_CR75","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1084\/jem.20131424","volume":"211","author":"JQ Wang","year":"2014","unstructured":"Wang JQ, Jeelall YS, Beutler B, Horikawa K, Goodnow CC. Consequences of the recurrent MYD88 (L265P) somatic mutation for B cell tolerance. J Exp Med. 2014;211:413\u201326.","journal-title":"J Exp Med"},{"key":"1152_CR76","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature09671","volume":"470","author":"VN Ngo","year":"2011","unstructured":"Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011;470:115\u20139.","journal-title":"Nature"},{"key":"1152_CR77","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.semcancer.2016.07.001","volume":"39","author":"S Ntoufa","year":"2016","unstructured":"Ntoufa S, Vilia MG, Stamatopoulos K, Ghia P, Muzio M. Toll-like receptors signaling: a complex network for NF-kappaB activation in B-cell lymphoid malignancies. Semin Cancer Biol. 2016;39:15\u201325.","journal-title":"Semin Cancer Biol"},{"key":"1152_CR78","doi-asserted-by":"crossref","first-page":"3790","DOI":"10.1182\/blood-2013-12-543306","volume":"123","author":"A Mart\u00ednez-Trillos","year":"2014","unstructured":"Mart\u00ednez-Trillos A, Pinyol M, Navarro A, Aymerich M, Jares P, Juan M, et al. Mutations in TLR\/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome. Blood. 2014;123:3790\u20136.","journal-title":"Blood"},{"key":"1152_CR79","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/01.cji.0000211304.60126.8f","volume":"29","author":"BK Link","year":"2006","unstructured":"Link BK, Ballas ZK, Weisdorf D, Wooldridge JE, Bossler AD, Shannon M, et al. Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma. J Immunother. 2006;29:558\u201368.","journal-title":"J Immunother"},{"key":"1152_CR80","doi-asserted-by":"crossref","first-page":"6168","DOI":"10.1158\/1078-0432.CCR-07-0815","volume":"13","author":"JP Leonard","year":"2007","unstructured":"Leonard JP, Link BK, Emmanouilides C, Gregory SA, Weisdorf D, Andrey J, et al. Phase I trial of Toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non-Hodgkin\u2019s lymphoma. Clin Cancer Res. 2007;13:6168\u201374.","journal-title":"Clin Cancer Res"},{"key":"1152_CR81","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ccr.2009.08.019","volume":"16","author":"D Chauhan","year":"2009","unstructured":"Chauhan D, Singh AV, Brahmandam M, Carrasco R, Bandi M, Hideshima T, et al. Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. Cancer Cell. 2009;16:309\u201323.","journal-title":"Cancer Cell"},{"key":"1152_CR82","first-page":"236","volume":"13","author":"F Cottini","year":"2015","unstructured":"Cottini F, Anderson K. Novel therapeutic targets in multiple myeloma. Clin Adv Hematol Oncol. 2015;13:236\u201348.","journal-title":"Clin Adv Hematol Oncol"},{"key":"1152_CR83","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1038\/leu.2014.46","volume":"28","author":"A Ray","year":"2014","unstructured":"Ray A, Tian Z, Das DS, Coffman RL, Richardson P, Chauhan D, et al. A novel TLR-9 agonist C792 inhibits plasmacytoid dendritic cell-induced myeloma cell growth and enhance cytotoxicity of bortezomib. Leukemia. 2014;28:1716\u201324.","journal-title":"Leukemia"},{"key":"1152_CR84","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1756-9966-32-18","volume":"32","author":"RB Abdelwahed","year":"2013","unstructured":"Abdelwahed RB, Cosette J, Donnou S, Crozet L, Ouakrim H, Fridman WH, et al. Lymphoma B-cell responsiveness to CpG-DNA depends on the tumor microenvironment. J Exp Clin Cancer Res. 2013;32:18.","journal-title":"J Exp Clin Cancer Res"},{"key":"1152_CR85","doi-asserted-by":"crossref","first-page":"3944","DOI":"10.1002\/cncr.24473","volume":"115","author":"JS Weber","year":"2009","unstructured":"Weber JS, Zarour H, Redman B, Trefzer U, O\u2019day S, van den Eertwegh AJ, et al. Randomized phase 2\/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma. Cancer. 2009;115:3944\u201354.","journal-title":"Cancer"},{"key":"1152_CR86","doi-asserted-by":"crossref","first-page":"7126","DOI":"10.1200\/jco.2004.22.14_suppl.7126","volume":"22","author":"G Leichman","year":"2004","unstructured":"Leichman G, Gravenor D, Albert G, Schmalbach T. A TLR9 CpG immunomodulator in combination with chemotherapy as treatment for advanced non-small cell lung cancer (NSCLS), a randomized, controlled phase II study. J Clin Oncol. 2004;22:7126.","journal-title":"J Clin Oncol"},{"key":"1152_CR87","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.canlet.2015.11.029","volume":"373","author":"M Jordan","year":"2016","unstructured":"Jordan M, Waxman DJ. CpG-1826 immunotherapy potentiates chemotherapeutic and anti-tumor immune responses to metronomic cyclophosphamide in a preclinical glioma model. Cancer Lett. 2016;373:88\u201396.","journal-title":"Cancer Lett"},{"key":"1152_CR88","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.uct.2007.11.003","volume":"3","author":"B Jahrsd\u00f6rfer","year":"2008","unstructured":"Jahrsd\u00f6rfer B, Weiner GJ. CpG oligodeoxynucleotides as immunotherapy in cancer. Update Cancer Ther. 2008;3:27\u201332.","journal-title":"Update Cancer Ther"},{"key":"1152_CR89","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.radonc.2006.07.024","volume":"80","author":"KA Mason","year":"2006","unstructured":"Mason KA, Neal R, Hunter N, Ariga H, Ang K, Milas L. CpG oligodeoxynucleotides are potent enhancers of radio-and chemoresponses of murine tumors. Radiother Oncol. 2006;80:192\u20138.","journal-title":"Radiother Oncol"},{"key":"1152_CR90","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1158\/0008-5472.CAN-04-0926","volume":"64","author":"L Milas","year":"2004","unstructured":"Milas L, Mason KA, Ariga H, Hunter N, Neal R, Valdecanas D, et al. CpG oligodeoxynucleotide enhances tumor response to radiation. Cancer Res. 2004;64:5074\u20137.","journal-title":"Cancer Res"},{"key":"1152_CR91","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1158\/1078-0432.361.11.1","volume":"11","author":"KA Mason","year":"2005","unstructured":"Mason KA, Ariga H, Neal R, Valdecanas D, Hunter N, Krieg AM, et al. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy. Clin Cancer Res. 2005;11:361\u20139.","journal-title":"Clin Cancer Res"},{"key":"1152_CR92","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.molimm.2005.07.020","volume":"43","author":"WJ Sohn","year":"2006","unstructured":"Sohn WJ, Lee KW, Choi SY, Chung E, Lee Y, Kim TY, et al. CpG-oligodeoxynucleotide protects immune cells from \u03b3-irradiation-induced cell death. Mol Immunol. 2006;43:1163\u201371.","journal-title":"Mol Immunol"},{"key":"1152_CR93","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1097\/CJI.0b013e3181ab23f1","volume":"32","author":"DJ Betting","year":"2009","unstructured":"Betting DJ, Yamada RE, Kafi K, Said J, van Rooijen N, Timmerman JM. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma. J Immunother. 2009;32:622\u201331.","journal-title":"J Immunother"},{"key":"1152_CR94","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3816\/CLM.2000.n.005","volume":"1","author":"TL Warren","year":"2000","unstructured":"Warren TL, Dahle CE, Weiner GJ. CpG oligodeoxynucleotides enhance monoclonal antibody therapy of a murine lymphoma. Clin Lymphoma. 2000;1:57\u201361.","journal-title":"Clin Lymphoma."},{"key":"1152_CR95","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1182\/blood.V89.8.2994","volume":"89","author":"JE Wooldridge","year":"1997","unstructured":"Wooldridge JE, Ballas Z. KriegAM, Weiner GJ. Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Blood. 1997;89:2994\u20138.","journal-title":"Blood"},{"key":"1152_CR96","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1097\/CJI.0b013e318261e679","volume":"35","author":"DJ Betting","year":"2012","unstructured":"Betting DJ, Hurvitz SA, Steward KK, Yamada RE, Kafi K, van Rooijen N, et al. Combination of cyclophosphamide, rituximab, and intratumoral CpG oligodeoxynucleotide successfully eradicates established B cell lymphoma. J Immunother. 2012;35:534\u201343.","journal-title":"J Immunother"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-017-1152-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T19:34:27Z","timestamp":1750016067000},"score":1,"resource":{"primary":{"URL":"http:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-017-1152-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,27]]},"references-count":96,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["1152"],"URL":"https:\/\/doi.org\/10.1186\/s12967-017-1152-5","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,27]]},"article-number":"51"}}